Business Context and Reporting Period
This Form 8-K was filed by Ventrus Biosciences, Inc. on November 25, 2013. The report discloses a material corporate event regarding the company's clinical development program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical milestone and does not contain financial statements.
Material Changes
The primary material event reported is the completion of patient enrollment in the company's second pivotal Phase 3 clinical trial for diltiazem cream (VEN 307), indicated for the treatment of anal fissure.
Outlook and Management Commentary
Management announced the enrollment milestone via a press release attached as Exhibit 99.1. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the announcement of the trial status.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on trial design and next steps.
- Confirm the regulatory status of diltiazem cream (VEN 307) for anal fissure.
- Review subsequent filings for data readouts from the completed Phase 3 trial.
- Note the discrepancy between the request metadata ("Assembly Biosciences") and the filing registrant ("Ventrus Biosciences").